Clinical Trial

Triple Therapy for Intermediate-advanced HCC With BDTT (TALENP002)

Recruiting
View on ClinicalTrials.gov →
Summary
This is a multicenter, Single-arm, Real-world Study to evaluate the efficacy and safety of Transcatheter arterial chemoembolization (TACE), Lenvatinib combined with Tislelizumab (Triple Therapy) for patients with Hepatocellular Carcinoma (HCC) with bile duct tumor thrombus (BDTT).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-09-17; most recent amendment 2024-10-11.
Status change: Not Yet Recruiting → Recruiting 2024-10-11
Trial Details
NCT Number NCT06602011
Lead Sponsor Fujian Provincial Hospital
Conditions Hepatocellular Carcinoma
Enrollment 20 participants
Start Date 2024-09-30
Primary Completion 2027-07-01 (estimated)
Study Completion 2028-10-01 (estimated)
Updated on ClinicalTrials.gov 2024-10-15